DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20210960

HER-2 neu expression in surface epithelial ovarian tumors and its relationship with clinic-pathological parameters: a pilot study

Abhimanyu Grover, Madhusmita Mohanty, Kanakalata Dash

Abstract


Background: Ovarian cancer is one of the major source of morbidity and mortality in women among all gynecological malignancies. Her2/neu expression in ovarian carcinoma has not been studied extensively in ovarian surface epithelial carcinoma. It's can be utilized towards future proposed studies as a targeted therapy in new era of treatment for ovarian malignancies.

Methods: It was a prospective study carried for 2 years. Hematoxylin and eosin stain was studied, grading, staging was evaluated for all the cases. Immunohistochemical staining with HER2/neu was done, evaluation done by 3 independent pathologists, correlation of HER2/neu with histological type, grade and stage was done.  

Results: The present study included 33 cases of histologically proven epithelial ovarian neoplasm with mean age of 44.5±25.55 years. Serous type constitutes majority of cases (48.48%), maximum number of cases was in high grade (57.57%) and high stage (40.74%). Majority of tumors showed negative expression of HER2/neu i.e. 42.42%. The current study found no significant correlation between HER2/neu expression and histological type, histological grade, extent of tumor (T stage) and distant metastasis. But we found a significant correlation between nodal metastasis and HER2/neu expression.

Conclusions: HER2/neu therapy can be given in borderline and low grade tumor compared to high grade tumor.


Keywords


Surface epithelial tumor, HER2/neu, Immunohistochemistry

Full Text:

PDF

References


Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. Cancer J Clin. 2018;68:284-96.

Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med. 2017;14:9-32.

Iqbal N, Iqbal N. Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications. Mol Biol Int. 2014;2014:852748.

Fukushige SI, Matsubara K, Yoshida MI, Sasaki MO, Suzuki TO, Semba K, et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Molecul Cellul Biol. 1986;6(3):955-8.

Reichelt U, Duesedau P, Tsourlakis MC, Quaas A, Link BC, Schurr PG, et al. Frequent homogeneous HER-2 amplification in primary and metastatic adenocarcinoma of the esophagus. Modern Pathol. 2007;20(1):120-9.

Prat J. Ovary, Fallopian Tube, and Primary Peritoneal Carcinoma. AJCC Cancer Staging Manual, Eight Edition. 2015;55:689-98.

Cirstea AE, Stepan AE, Margaritescu C, Zavoi RE, Olimid DA, Simionescu CE. The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors. Rom J Morphol Embryol. 2017;58(4):1269-73.

Nielsen JS, Jakobsen E, Hølund B, Bertelsen K, Jakobsen A. Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gynecol Canc. 2004;14(6).

Goel S, Mehra M, Yadav A, Sharma M.A Comparative study of HER-2/neu Oncogene in benign and malignant ovarian tumors. Int J Scient Stud. 2014;2:21-7 .

Showeil R, Romano C, Valganon M, Lambros M, Trivedi P, Van Noorden S, et al. The status of epidermal growth factor receptor in borderline ovarian tumours. Oncotarget. 2016;7(9):10568.

Asadinejad E, Abdirad A, Nili F, Soleimani V. HER2 Overexpression in Borderline and Malignant Ovarian Tumors: A Cross-sectional Study in an Iranian Population and Literature Review. Mid East J Canc. 2018;9(4):300-9.

Ndukwe CO, Asomugha LA, Ukah CO. Profile of human epidermal growth factor receptor 2 expression in epithelial ovarian carcinomas: A multicenter study from southeast Nigera. J Scientif Soc. 2018 ;5:57-62.

Cirstea AE, Stepan AE, Margaritescu C, Zavoi RE, Olimid DA, Simionescu CE. The immunoexpression of EGFR, HER2 and HER3 in malignant serous ovarian tumors. Rom J Morphol Embryol. 2017;58(4):1269-73.